Orthogonal Methods
Orthogonal Analytics: How Much Characterization Is Enough?
David Alvaro, Ph.D.
Pharma's Almanac
PAO-10-26-PA-14Oct 22, 2026
SmartScale
Phase-Appropriate CMC Requires a New Phase-Appropriate Manufacturing Model
Jesse McCool, Ph.D.
GBI Biomanufacturing
PAO-10-26-CL-05Oct 21, 2026
Data-Driven Mfg
Data-Driven Manufacturing and Digital Twins Across the Biologics Network
Jihyeon Oh; Hongwoo Joo
Samsung Biologics
PAO-10-26-CL-03Oct 21, 2026
CLD
Can Mammalian Cell-Line Engineering Become a High-Throughput Design Problem?
Pharma's Almanac
PAO-10-26-PA-09Oct 14, 2026
Bioprocessing
Bioprocessing and Capacity Trends: Growth Despite Continued Uncertainty
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-10-26-PA-06Oct 9, 2026
DS + DP Integration
Integrating Drug Substance and Drug Product to Reduce Risk Across Development
Dörthe Ackenhausen
IDT Biologika
PAO-09-26-CL-02Sep 24, 2026
Multi-Modality CDMO
The Rise of the Multi-Modality CDMO: Why Clients Need More Than Capacity
Kamal Preet
OneSource Specialty Pharma
PAO-09-26-CL-06Sep 24, 2026
DSP
Why More Product Upstream Creates New Pressure Downstream
Pharma's Almanac
PAO-09-26-PA-15Sep 21, 2026
BsAbs in Oncology
Bispecific Antibodies Move Into the Heme-Onc Mainstream
David Alvaro, Ph.D.
Pharma's Almanac
PAO-09-26-PA-12Sep 16, 2026
Biosimilars
The Global Division of Labor Behind the Coming Oncology Biosimilar Wave
Pharma's Almanac
PAO-09-26-PA-18Sep 15, 2026
Partnership
Samsung Biologics Signs USD 262 Million Manufacturing Agreement with European Pharmaceutical Company
Samsung Biologics
PR-09-26-02Sep 10, 2026
Single-Use
The Changing Economics of Single-Use Biomanufacturing
Pharma's Almanac
PAO-09-26-PA-08Sep 10, 2026
Biologics Platform
Platform-Based Drug Substance Development: Applying Prior Knowledge Across Modalities
Mathias Kahl
IDT Biologika
PAO-08-26-CL-03Sep 9, 2026
Productivity
The Next Productivity Leap in Mammalian Cell Culture
Pharma's Almanac
PAO-09-26-PA-03Sep 3, 2026
Funding
Samsung Biologics Announces KRW 3 Trillion Rights Offering to Fund Its Next-Phase Expansion
Samsung Biologics
PR-08-26-03Sep 1, 2026
Capacity
Is the Bioreactor Arms Race Over?
David Alvaro, Ph.D.
Pharma's Almanac
PAO-09-26-PA-01Sep 1, 2026
Lipase Risk
An Integrated Analytical Approach to Lipase Risk Management in Biologics Development
Kyeyeon Hur, Ph.D.; Jimin Kim, Ph.D.; Minjeong Lee; Soojeong Oh; Woojung Jun
Samsung Biologics
PAO-08-26-CL-10Aug 31, 2026
Prevention
Preventive Therapeutics Beyond Vaccines
David Alvaro, Ph.D.
Pharma's Almanac
PAO-08-26-PA-13Aug 18, 2026
Masked Antibody
Expanding the Oncology Therapeutic Window Through Masked Antibody Technology
Sean McCarthy, Ph.D; David Alvaro, Ph.D.
CytomX Therapeutics
PAO-08-26-CL-09Aug 14, 2026
Self-Injection
The Quiet Revolution in How We Take Our Medicine
Ravi Kumar
OneSource Specialty Pharma
PAO-08-26-CL-06Aug 6, 2026